Teva Announces Plan to Sell its Active-Pharmaceutical Ingredient (API) Business, ‘TAPI,’ as a Strategic Move Towards Growth Teva disclosed today its decision to divest its active-pharmaceutical ingredient (API) business, known as “TAPI.” A prominent player in the global small-molecule API…
ROHTO Pharmaceutical Strengthens Global Presence with EMA Aesthetics Through Strategic Partnership EMA Aesthetics, a Dublin-based global aesthetics company, has announced a significant strategic and equity collaboration with ROHTO Pharmaceutical, a renowned Japanese multinational recognized for its innovative approaches in healthcare…
In Q4 2023, Sanofi experienced a robust sales growth of 9.3% at Constant Exchange Rates (CER) and an 8.2% increase in business EPS. Notable achievements include Specialty Care’s 13.7% growth fueled by the success of Dupixent and ALTUVIIIO launches, which…
Novo Nordisk’s sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023 PROFIT AND LOSS 2023 2022 Growthas reported Growthat CER* DKK million Net sales 232,261…
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that we have concluded investment agreement with Niremia Collective, a venture capital firm specializing in Well-being Technology-focused funds (Headquarters: California, USA; Representative: Naoko Okumoto,…
ObjectiveHealth, a leading integrated specialty research network and technology company, announced today that it has secured a strategic growth investment from Vitruvian Partners, a leading global growth-focused investment firm. ObjectiveHealth is an innovator in clinical research, seamlessly integrating clinical trials…
Lonza has reported sales of CHF 6.7 billion, sales growth of 7.9% AER2 (10.9%1 CER), and CHF 2 billion CORE EBITDA, resulting in a margin of 29.8%. The solid financial results were driven by the Biologics and Small Molecules divisions, with a…
AbbVie (NYSE: ABBV) strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million (S$301 million) expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie’s…
Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share. Edgewise anticipates gross proceeds from the…
ICON plc, (NASDAQ: ICLR), a world-leading clinical research organisation powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2024. For the full year 2024, revenue is expected to be in the range of $8,400 – $8,800 million,…
Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 4 million shares of Pfizer common stock at a price of $27.35…
Clarametyx Biosciences Inc. (“Clarametyx”), a clinical stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, today announced the successful completion of a $33 million Series A round. The proceeds from the round will enable the…
